Key result
Adjuvant trastuzumab was associated with an increased risk of incident heart failure compared to chemotherapy alone in the first 1.5 years (HR 5.77; 95% CI 4.38-7.62; P<0.001), but not thereafter.
Why the study?
Does adjuvant trastuzumab increase the risk of incident heart failure in female breast cancer patients receiving chemotherapy?
Population
19,074 female breast cancer patients in Ontario treated with adjuvant chemotherapy, excluding those with…
Comparison
Adjuvant trastuzumab added to chemotherapy vs Adjuvant chemotherapy alone
Design
Cohort
Follow-up
median 5.9 years
Authors
Loading...
Trastuzumab-related HF risk appears confined to active treatment; leaves open need for long-term surveillance in survivors.
Cohort (n=19,074)
Does adjuvant trastuzumab increase the risk of incident heart failure in female breast cancer patients receiving chemotherapy?
Hazard Ratio: 5.77 (95% CI 4.38–7.62)
Absolute Event Rate: 5.2% vs 2.5%
p-value: p=< .001
Adjuvant trastuzumab significantly increases the risk of incident heart failure during the first 1.5 years of treatment, but this risk does not persist long-term, suggesting routine intensive cardiac monitoring may not be necessary after completing therapy.
Goldhar et al. (2015) conducted a cohort in breast cancer (n=19,074). Adjuvant trastuzumab vs. chemotherapy alone was evaluated on new diagnosis of heart failure (HR 5.77, 95% CI 4.38 to 7.62, p=< .001). Adjuvant trastuzumab was associated with an increased risk of incident heart failure compared to chemotherapy alone in the first 1.5 years (HR 5.77; 95% CI 4.38-7.62; P<0.001), but not thereafter.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: